Keros Therapeutics (NASDAQ:KROS) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of Keros Therapeutics (NASDAQ:KROS) from a strong sell rating to a hold rating in a report published on Monday,Wall Street Zen reports.

Several other research analysts have also commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Keros Therapeutics in a report on Wednesday, August 12th. Zacks Research raised shares of Keros Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 27th. Leerink Partners decreased their price objective on shares of Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating for the company in a research note on Tuesday, August 4th. HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of Keros Therapeutics in a research note on Tuesday, August 4th. Finally, Wells Fargo & Company dropped their price objective on shares of Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating for the company in a research report on Tuesday, August 4th. Four analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $21.40.

Keros Therapeutics Stock Performance

Keros Therapeutics stock opened at $9.17 on Monday. The stock’s 50-day moving average is $11.14 and its 200-day moving average is $11.87. Keros Therapeutics has a 12 month low of $9.10 and a 12 month high of $22.55.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings data on Thursday, November 5th. The company reported $0.70 earnings per share for the quarter, beating the consensus estimate of ($0.96) by $1.66. Keros Therapeutics had a negative return on equity of 21.40% and a negative net margin of 256.60%. The business had revenue of $40.01 million for the quarter, compared to analyst estimates of $14.76 million. Sell-side analysts expect that Keros Therapeutics will post -5.27 EPS for the current year.

Keros Therapeutics declared that its Board of Directors has approved a share buyback program on Wednesday, September 9th that authorizes the company to buy back $5 million in outstanding shares. This buyback authorization authorizes the company to reacquire up to 2.3% of its shares through open market purchases. Stock buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.

Insider Activity at Keros Therapeutics

In other news, insider Lorena Raquel Lerner sold 3,568 shares of the company’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $10.29, for a total value of $36,714.72. Following the completion of the sale, the insider owned 27,559 shares of the company’s stock, valued at $283,582.11. This represents a 11.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 5,343 shares of company stock worth $54,985 in the last 90 days. Insiders own 12.60% of the company’s stock.

Institutional Investors Weigh In On Keros Therapeutics

Several hedge funds have recently modified their holdings of the stock. BlackRock Inc. purchased a new position in Keros Therapeutics in the 2nd quarter worth approximately $29,898,000. Nantahala Capital Management LLC acquired a new stake in Keros Therapeutics in the second quarter valued at approximately $15,091,483. Dimensional Fund Advisors LP grew its position in Keros Therapeutics by 453.9% in the first quarter. Dimensional Fund Advisors LP now owns 321,360 shares of the company’s stock valued at $3,547,000 after acquiring an additional 263,347 shares in the last quarter. ADAR1 Capital Management LLC purchased a new stake in shares of Keros Therapeutics during the second quarter valued at approximately $2,641,000. Finally, Man Group plc purchased a new stake in shares of Keros Therapeutics during the second quarter valued at approximately $1,664,000. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for diseases caused by dysfunctional signaling in the transforming growth factor-beta (TGF-β) superfamily of proteins. The company uses its research platform to design therapies intended to regulate signaling pathways involved in blood-cell production, bone health and cardiovascular function.

Keros’ investigational pipeline has included elritercept (KER-050), an activin receptor type IIA ligand trap being studied for hematologic conditions such as lower-risk myelodysplastic syndromes and myelofibrosis.